The chemical name is 4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole hydrochloride.

**INDICATIONS**

ANTISEDAN (atipamezole hydrochloride) is a synthetic α₂-antagonist. It is rapidly absorbed following oral or parenteral administration.

**DOSE AND ADMINISTRATION**

Atipamezole is administered intramuscularly (IM) for the reversal of sedation and antinociception regardless of the route used for DOMITOR or DEXDOMITOR. The atipamezole dose for the reversal of DOMITOR or DEXDOMITOR treatment of 1 mg/kg IM is effective.

The dose of DOMITOR is calculated based on the patient’s body weight.

**INDICATIONS:**

For intramuscular use in dogs only

**CLINICAL PHARMACOLOGY:**

Atipamezole is a potent α₂-antagonist which selectively and competitively inhibits α₂-adrenergic receptors. The result of atipamezole administration in the dog is the rapid recovery from the sedative and analgesic effects produced by the α₂-agonist. Signs were dose-related and included excitement, panting, trembling, and >90% had a normal pedal reflex response. Responses in dogs treated with α₂-agonist treatment, and is probably due to

**ADVERSE REACTIONS:**

Occasional vomiting may occur. At times, a period of excitement or labored breathing may be observed. Dogs may show signs of hyperventilation, which may include hypersalivation, diarrhea, and tremors.

**PRECAUTIONS:**

1. Handling:
   - Atipamezole should be handled with care. The potent α₂-antagonist properties of atipamezole should be considered in the handling of dogs treated with α₂-agonist.

2. Analgesia reversal:
   - Atipamezole reverses analgesic effects as well as sedative effects.

3. Analgesia reversal:
   - Atipamezole reverses analgesic effects as well as sedative effects.

4. Debilitated dogs:
   - Additional procedures for the control of pain may be required.

5. INDICATIONS:
   - ANTISEDAN (atipamezole hydrochloride) is a synthetic α₂-antagonist.

6. Minimum age and weight:
   - Dogs ≥ 3 months of age and ≥ 10 kg

7. Handling:
   - Users with cardiovascular disease (for example, hypertension or ischemic heart disease) should take special precautions to avoid any exposure to this product.

8. Handling:
   - Users with cardiovascular disease (for example, hypertension or ischemic heart disease) should take special precautions to avoid any exposure to this product.

9. Handling:
   - Users with cardiovascular disease (for example, hypertension or ischemic heart disease) should take special precautions to avoid any exposure to this product.

10. Handling:
    - Users with cardiovascular disease (for example, hypertension or ischemic heart disease) should take special precautions to avoid any exposure to this product.

**Table 1: Dosing for reversal of IM dexmedetomidine- or medetomidine-induced sedation:**

<table>
<thead>
<tr>
<th>Weight (lbs)</th>
<th>Dose (mcg/kg)</th>
<th>Volume (mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 - 9</td>
<td>0.029 - 0.053</td>
<td>1 - 2</td>
</tr>
<tr>
<td>10 - 18</td>
<td>0.053 - 0.106</td>
<td>2 - 4</td>
</tr>
<tr>
<td>19 - 25</td>
<td>0.106 - 0.212</td>
<td>4 - 8</td>
</tr>
<tr>
<td>26 - 40</td>
<td>0.212 - 0.424</td>
<td>8 - 16</td>
</tr>
</tbody>
</table>

**Table 2:**

<table>
<thead>
<tr>
<th>Weight (lbs)</th>
<th>Dose (mcg/kg)</th>
<th>Volume (mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 - 9</td>
<td>0.029 - 0.053</td>
<td>1 - 2</td>
</tr>
<tr>
<td>10 - 18</td>
<td>0.053 - 0.106</td>
<td>2 - 4</td>
</tr>
<tr>
<td>19 - 25</td>
<td>0.106 - 0.212</td>
<td>4 - 8</td>
</tr>
<tr>
<td>26 - 40</td>
<td>0.212 - 0.424</td>
<td>8 - 16</td>
</tr>
</tbody>
</table>

**CONTRAINDICATIONS:**

- Atipamezole is contraindicated in dogs with known hypersensitivity to atipamezole or any component of the formulation.

- α₂-Antagonists are contraindicated in dogs with known hypersensitivity to α₂-agonists or any component of the formulation.

**EFFECTIVENESS:**

One hundred and nine dogs received atipamezole in the field study (55 dogs treated with a 1 mg/kg dose, 54 dogs treated with a 2 mg/kg dose).

**Indications:**

The chemical name is 4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole hydrochloride.

**INDICATIONS:**

Atipamezole is a synthetic α₂-antagonist.

**EFFECTIVENESS:**

One hundred and nine dogs received atipamezole in the field study (55 dogs treated with a 1 mg/kg dose, 54 dogs treated with a 2 mg/kg dose).
**ADVERSE REACTIONS:** Occasionally vomiting may occur. At times, a period of excitement or apprehensiveness may occur in normal animals with appropriate doses of atipamezole. The rapid return from the sedative and analgesic effects produced by the dog is the rapid recovery from the sedative and analgesic effects produced by the alpha2-adrenergic agonists dexmedetomidine or medetomidine. Atipamezole does not reverse the sedative and analgesic effects produced by the alpha2-adrenergic agonists dexmedetomidine or medetomidine. Atipamezole does not reverse the sedative and analgesic effects produced by the alpha2-adrenergic agonists dexmedetomidine or medetomidine. 

**ANIMAL SAFETY:** Atipamezole was tolerated in healthy dogs receiving 10X the recommended dose of atipamezole. Atipamezole was administered to dogs receiving atipamezole (57% could stand). Within 15 minutes, 96% of dexmedetomidine treated dogs were standing, 89% responded normally to sound, 86% had a normal muscle tone of body and tail, 87% responded normally to painful stimuli, and 84% of dogs could follow a person by moving their eyes. Within 15 minutes, 74% of dogs treated with atipamezole were standing, 71% responded normally to sound, 63% had a normal muscle tone of body and tail, 62% responded normally to painful stimuli, and 60% of dogs could follow a person by moving their eyes. 

**CONTRAINDICATIONS:** Atipamezole is contraindicated in dogs with a known hypersensitivity to the drug. Administration of atipamezole is contraindicated in dogs with a known hypersensitivity to the drug. Administration of atipamezole is contraindicated in dogs with a known hypersensitivity to the drug. 

**ANALGESIA REVERSAL:** Atipamezole reverses analgesic effects as well as sedative effects. Atipamezole reverses analgesic effects as well as sedative effects. Atipamezole reverses analgesic effects as well as sedative effects. 

**ADVERSE REACTIONS:** Occasionally vomiting may occur. At times, a period of excitement or apprehensiveness may occur in normal animals with appropriate doses of atipamezole. The rapid return from the sedative and analgesic effects produced by the dog is the rapid recovery from the sedative and analgesic effects produced by the alpha2-adrenergic agonists dexmedetomidine or medetomidine. Atipamezole does not reverse the sedative and analgesic effects produced by the alpha2-adrenergic agonists dexmedetomidine or medetomidine. Atipamezole does not reverse the sedative and analgesic effects produced by the alpha2-adrenergic agonists dexmedetomidine or medetomidine. Atipamezole does not reverse the sedative and analgesic effects produced by the alpha2-adrenergic agonists dexmedetomidine or medetomidine. 

**ADVERSE REACTIONS:** Occasionally vomiting may occur. At times, a period of excitement or apprehensiveness may occur in normal animals with appropriate doses of atipamezole. The rapid return from the sedative and analgesic effects produced by the dog is the rapid recovery from the sedative and analgesic effects produced by the alpha2-adrenergic agonists dexmedetomidine or medetomidine. Atipamezole does not reverse the sedative and analgesic effects produced by the alpha2-adrenergic agonists dexmedetomidine or medetomidine. Atipamezole does not reverse the sedative and analgesic effects produced by the alpha2-adrenergic agonists dexmedetomidine or medetomidine. Atipamezole does not reverse the sedative and analgesic effects produced by the alpha2-adrenergic agonists dexmedetomidine or medetomidine.